Adults

The new Consolidated guidelines on HIV, viral hepatitis and STI prevention, diagnosis, treatment and care for key populations outline a public health response for 5 key populations (men who have sex with men, trans and gender diverse people, sex workers, people who inject drugs and people in prisons and other closed settings). They present and discuss new recommendations and consolidate a range of recommendations and guidance from current WHO guidelines.

This document is written for national HIV surveillance programme staff responsible for monitoring trends in country HIV epidemics. Its purpose is to describe how routine prevention of mother-to-child transmission of HIV (PMTCT) programme data can be used to conduct HIV surveillance among pregnant women attending antenatal clinics (ANC). These guidelines assume that surveillance programmes have already assessed the readiness of routine programme data to be used for surveillance. WHO’s 2013 Guidelines for assessing the utility of prevention of mother-to-child transmission (PMTCT) programme data for HIV sentinel surveillance among pregnant women describes these assessment methods.

Supplement to consolidated guidelines on HIV testing services

In this report, UNAIDS is announcing that 18.2 million people now have access to HIV treatment. The Fast-Track response is working. Increasing treatment coverage is reducing AIDS-related deaths among adults and children. But the life-cycle approach has to include more than just treatment. Tuberculosis (TB) remains among the commonest causes of illness and death among people living with HIV of all ages, causing about one third of AIDS-related deaths in 2015. These deaths could and should have been prevented.

PMTCT & Paediatric HIV/TB Lessons & Results from Using New WHO-UNICEF HIV-Adapted Community Materials

Greatly expanded access to routine viral load testing will be a game-changer in the global response to AIDS. Routine viral load tests improve treatment quality and individual health outcomes for people living with HIV, contribute to prevention, and potentially reduce resource needs for costly second- and third-line HIV medicines.